Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's
JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients
2015. Vogel, Carl-Wilhelm, Paul W. Finnegan, and David C. Fritzinger. "Humanized Cobra Venom Factor: Structure, Activity, And Therapeutic Efficacy In Preclinical